Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics. (Q38133766)

29 August 2017

Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics. (English)

1 reference

29 August 2017

0 references

Mark Sanford

1

1 reference

PubMed ID

23999971

29 August 2017

language of work or name

1 reference

1 November 2013

1 reference

29 August 2017

1 reference

29 August 2017

27

1 reference

29 August 2017

11

1 reference

29 August 2017

989-1002

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-013-0107-5

29 August 2017

0 references

cites work

Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Persistent pain and well-being: a World Health Organization Study in Primary Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Prevalence of pain in patients with cancer: a systematic review of the past 40 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Ziconotide for treatment of severe chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: first demonstration of N-channel function in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Continuous Intrathecal Infusion of Ziconotide for Treatment of Chronic Malignant and Nonmalignant Pain Over 12 Months: A Prospective, Open-label Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Long-term intrathecal ziconotide for chronic pain: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

An Open-Label, Multicenter Study of the Safety and Efficacy of Intrathecal Ziconotide for Severe Chronic Pain When Delivered via an External Pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Increased risk of suicide under intrathecal ziconotide treatment? - a warning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Ziconotide combination intrathecal therapy: rationale and evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0107-5

Considerations and methodology for trialing ziconotide

21 January 2018

1 reference

12 December 2020

Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC)

1 reference

12 December 2020

Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.

1 reference

12 December 2020

Intrathecal therapy for cancer and non-cancer pain.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients

1 reference

12 December 2020

Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery

1 reference

12 December 2020

Italian registry on long-term intrathecal ziconotide treatment.

1 reference

12 December 2020

Polyanalgesic Consensus Conference 2012: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel

1 reference

12 December 2020

1 reference

12 December 2020

Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM).

1 reference

12 December 2020

Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain

1 reference

12 December 2020

10.1007/S40263-013-0107-5

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23999971